AKBA
Compiled from published pharmacological and botanical literature. Not independently verified by Herbuno. Spotted an error or have a correction? Flag it below →
| Chemical Class | Pentacyclic triterpenoid (ursane-type boswellic acid derivative) |
| Molecular Formula / CAS | C₃₂H₄₈O₅ · CAS 67416-61-9 |
| Primary Botanical Source(s) | Frankincense / Boswellia serrata (also B. carterii, B. sacra) |
| Plant Part | Oleo-gum resin |
| Typical Content | The single most potent 5-lipoxygenase-inhibiting boswellic acid, present as a minor fraction of total boswellic acid content and typically concentrated to 10–30% in dedicated AKBA extracts |
| Solubility / Format | Available as standardised extract powders at multiple concentrated potency grades |
| Sourcing Status | Product-live — genuine match via Herbuno’s AKBA-concentrated frankincense extract line, distinct from Herbuno’s general Boswellic Acids products |
| Buy from Herbuno | AKBA 30% Powder (Indian Frankincense Extract) · AKBA 10% Powder |
Name origin: AKBA is the standard abbreviation for 3-O-acetyl-11-keto-β-boswellic acid, a name that describes its exact chemical structure — an acetylated, keto-substituted derivative of β-boswellic acid, one of the resin acids of Boswellia oleo-gum resin. Traditional use: Frankincense resin has been burned as incense and used medicinally across Middle Eastern, North African, and South Asian traditions for millennia, valued in Ayurvedic medicine (as shallaki) specifically for joint pain and inflammatory conditions long before its individual resin acids were chemically distinguished from one another. Research trajectory: Research through the 1990s identified AKBA specifically, among the six major boswellic acids, as by far the most potent inhibitor of 5-lipoxygenase — the enzyme responsible for producing pro-inflammatory leukotrienes — which shifted commercial and research interest toward AKBA-concentrated extracts distinct from general boswellic-acid-standardised products; this mechanistic finding subsequently drove a substantial clinical trial programme testing AKBA-enriched extracts directly against osteoarthritis. Commercial source: Boswellia serrata oleo-gum resin is the standard commercial source of AKBA, and Herbuno’s dedicated AKBA-concentrated extracts reflect this well-established, genuine botanical match, distinguished from Herbuno’s general Boswellic Acids product line.
Evidence for AKBA Applications
Structure-activity research comparing the major boswellic acids found that AKBA was markedly more potent at inhibiting 5-lipoxygenase than β-boswellic acid, which lacks the 11-keto functional group, with the 11-keto function shown to be essential for meaningful 5-LOX inhibitory activity (Sailer et al. 1996). AKBA acts through a distinctive, non-redox, non-competitive, calcium-dependent binding mechanism at a regulatory site on the 5-lipoxygenase enzyme, distinguishing its mechanism from conventional NSAID action on cyclooxygenase. Claim strength: Moderate.
A double-blind, randomised, placebo-controlled 90-day trial tested “5-Loxin,” a Boswellia serrata extract standardised to 30% AKBA, at 100 mg and 250 mg daily doses in 75 knee osteoarthritis patients, finding significant improvements in pain and physical function scores (VAS, Lequesne’s Functional Index, WOMAC) as early as day 7, along with a significant reduction in the cartilage-degrading enzyme matrix metalloproteinase-3 in synovial fluid (Sengupta et al. 2008). This trial is one of the more frequently cited human clinical results specific to an AKBA-concentrated extract, as distinct from general boswellic acid products. Claim strength: Moderate.
A more recent multicenter, randomised, double-blind, placebo-controlled trial combining Boswellia serrata extract with celery seed (Apium graveolens) extract found improvements in knee osteoarthritis symptoms and cartilage degradation markers, attributing much of the anti-inflammatory mechanism specifically to AKBA’s 5-lipoxygenase-inhibiting activity within the combination formula (et al. 2024). Claim strength: Moderate.
Beyond osteoarthritis, AKBA has been investigated for a range of additional applications including inflammatory bowel disease, where boswellic acid extracts have shown activity comparable to mesalazine in some studies, and for neuroprotective, hepatoprotective and antitumor activity in preclinical models, often via Nrf2 pathway activation. This breadth of preclinical interest reflects AKBA’s status as the most pharmacologically potent individual boswellic acid, though most applications beyond osteoarthritis remain at the preclinical research stage. Claim strength: Emerging.
Formulators should distinguish AKBA-concentrated extracts, standardised specifically to enrich this single most potent boswellic acid fraction, from Herbuno’s general Boswellic Acids products, which are standardised to total boswellic acid content across all six major boswellic acids without specifically concentrating AKBA. Products marketed on the strength of the 5-Loxin-style clinical research should specify AKBA percentage explicitly rather than a general boswellic acid figure. Claim strength: Moderate.
Dosage & Formulator Specification
The clinical trial literature on AKBA-concentrated extract for osteoarthritis has used doses of 100–250 mg AKBA-standardised extract daily (delivering roughly 30–75 mg AKBA/day at 30% standardisation), with symptom improvement reported as early as one week into treatment in the better-controlled trials.
Analytical quantification of AKBA is performed by HPLC, and because AKBA is one of six major boswellic acids present in Boswellia resin, formulators should request AKBA-specific chromatographic data rather than a total boswellic acid percentage, which would not distinguish AKBA content from the less potent, non-acetylated or non-keto boswellic acid fractions.
Bioavailability has historically been a limiting factor for AKBA and related boswellic acids; formulators developing finished products should be aware that absorption-enhancement technologies (such as phospholipid complexes or co-formulation with bioavailability enhancers) are commonly used in the commercial AKBA supplement space to address this documented limitation.
Regulatory positioning for AKBA follows established Boswellia serrata botanical-ingredient precedent in most markets, given frankincense resin’s centuries-long traditional medicinal use; no AKBA-specific regulatory limit exists. Formulators making osteoarthritis-related claims should base them on the AKBA-concentrated extract clinical literature rather than the broader, less-concentrated general boswellic acid research.
Frequently Asked Questions — AKBA
AKBA (3-O-acetyl-11-keto-β-boswellic acid) is the single most potent of the six major boswellic acids at inhibiting the inflammatory enzyme 5-lipoxygenase. Herbuno’s dedicated AKBA products are concentrated specifically for this fraction, while the general Boswellic Acids products are standardised to total boswellic acid content across all six.
A randomised, placebo-controlled 90-day trial of a 30%-AKBA-standardised extract found significant improvements in knee osteoarthritis pain and function scores within as little as one week, along with reduced levels of a cartilage-degrading enzyme in synovial fluid. A more recent multicenter trial combining Boswellia and celery seed extract found similar benefits.
Structure-activity research found that boswellic acids lacking the 11-keto functional group, such as plain β-boswellic acid, show much weaker 5-lipoxygenase inhibitory activity than AKBA. This structural feature is central to why AKBA specifically is targeted for concentration in dedicated extracts.
Preclinical research has explored AKBA for inflammatory bowel disease, neuroprotection, liver protection and antitumor activity, often through Nrf2 pathway activation. Most of these applications remain at the animal and cell-culture research stage rather than confirmed in human trials, unlike the more established osteoarthritis evidence.
Related compounds: Boswellic Acid, Alpha-Pinene